



July 20, 2019

**BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001

Scrip code: 532531

**The National Stock Exchange of India Limited**

Exchange Plaza , Bandra-Kurla Complex  
Bandra (E) Mumbai - 400 051

Scrip code: STAR

Dear Sirs,

**Sub: Press Release**

Please find attached press release issued by the Company titled:

**“Strides announces successful completion of US FDA inspection at its  
flagship facility in Bangalore”**

Thanking you,

For **Strides Pharma Science Limited**

A handwritten signature in blue ink that reads 'Manjula R.'.

**Manjula Ramamurthy**  
**Company Secretary**



**Strides Pharma Science Limited**

(Formerly Strides Shasun Limited)

CIN: L24230MH1990PLC057062

**Corp Off:** Strides House, Bilekahalli, Bannerghatta Road, Bangalore - 560 076, India

Tel: +91 80 6784 0000 Fax: +91 80 6784 0700

**Regd Off:** 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India

Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942

info@strides.com; www.strides.com

---

## Strides announces successful completion of US FDA inspection at its flagship facility in Bangalore

**Bangalore, India, July 20, 2019** - Strides Pharma Science Limited (BSE: 532531, NSE: STAR) today announced that its formulation facility in Bangalore underwent a USFDA inspection that ended on May 24<sup>th</sup>, 2019. The inspection was completed successfully with a Voluntary Action Indicated (VAI) classification.

The flagship facility in Bangalore is the largest manufacturing facility for the company with capabilities to produce finished dosage formulation products across multiple dosage formats including tablet, capsules, ointments, creams and liquids. The facility services the key regulated markets of the US, Europe, and Australia.

### ABOUT STRIDES

---

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical Company headquartered in Bangalore, India. The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy along with an institutional business to service donor-funded markets. The Company’s global manufacturing sites are located in India- Bangalore (two sites), Pondicherry, and Chennai, Singapore, Italy- Milan, and Kenya- Nairobi. The Company focusses on “difficult to manufacture” products that are sold in over 100 countries. Additional information is available at the Company’s website at [www.strides.com](http://www.strides.com)

### For further information, please contact:

<p><b>Strides</b> <b>Badree Komandur</b> Executive Director - Finance +91 80 6784 0747</p> <p><b>Investor Relations:</b> <b>Kannan. N:</b> +91 98450 54745 <b>Vikesh Kumar:</b> +91 80 6784 0827 <b>Sandeep Baid:</b> +91 80 6784 0791 Email: <a href="mailto:sandeep.baid@strides.com">sandeep.baid@strides.com</a></p> <p><b>Strides Pharma Science Limited</b> (Formerly Strides Shasun Limited) CIN: L24230MH1990PLC057062</p> <p>Regd. Office: 201, 'Devavrata', Sector - 17, Vashi, Navi Mumbai - 400 703</p> <p>Corp. Office: Strides House, Bannerghatta Road, Bangalore – 560076</p>	<p><b>PR Consultancy</b> Fortuna PR K Srinivas Reddy: +91 90005 27213 <a href="mailto:srinivas@fortunapr.com">srinivas@fortunapr.com</a></p> <p>K Priya: +91 95354 25418 <a href="mailto:priya@fortunapr.com">priya@fortunapr.com</a></p>
---	---